The anxiolytic etifoxine can continue to be given to patients with anxiety disorders provided they have not previously experienced severe dermatological or hepatic side-effects after taking the drug, the European Medicines Agency has advised.
EU OKs Continued Use Of Etifoxine For Anxiety Despite Toxicity Concerns
The European Medicines Agency has also recommended that EU member states go ahead and approve Tiofarma’s midazolam nasal spray Nasolam for convulsive seizures, while a review of a lidocaine/prilocaine product from French firm International Drug Development has been stopped after the applicant withdrew its decentralized marketing authorization application.
